Clinico-pathological changes induced in @entity35 treated with XXXX -curing agent for @entity990 resin, @entity70930 .

@entity137 @entity37480 @entity66 @entity990 @entity70930 @entity6115 @entity2631 @entity194 @entity35 @entity121 @entity6558
@entity6115 -curing agent for @entity990 resin, @entity70930 (commercial name; @entity70930 ) has been suspected to have induced in the workers some @entity137 signs such as collagen disease like @entity2631 or @entity6558 . Subacute @entity137 of this agent was studied in @entity35 following repeated oral administration. The agent was given orally at 5 dose levels (25 mg/kg to 100 mg/kg per one dose) for periods ranging from 10 days to 4 weeks. After the completion of administration, clinico-biochemical tests and histopathological examinations were carried out. In a few cases, skeletal muscles and choroid plexus of the brain were examined by electronmicroscopy. Clinico-biochemical tests revealed some elevation of muscle-derived components such as GOT and CPK as seen in the @entity66 . Histologically, various degrees of @entity194 , degeneration and regeneration of muscle fibers and a numerical increase of interstitial cells were observed in the skeletal muscles. Electronmicroscopical examination of the gastrocnemius muscle revealed intrasarcoplasmic osmiophilic round-shaped inclusion bodies, sometimes with lamellar structure, which were suggestive of some @entity37480 . The epithelial cells of choroid plexus in the brain ventricles represented various degrees of vacuolar changes lightmicroscopically, which were suggested to be dilated smooth endoplasmic reticulum electronmicroscopically. Although @entity2631 -like changes were not observed in our experiments, the results suggest that this @entity6115 -curing agent for @entity990 resin could be one of the causative agents which induced @entity137 lesions like some collagen diseases including @entity121 in the workers. In addition, it is considered that the agent may have systemic @entity137 effects.
